Source: Health Products Regulatory Authority (IE) Revision Year: 2017 Publisher: Norton Healthcare Ltd, T/A IVAX Pharmaceuticals UK, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX, United Kingdom
Serenace 5 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Bright pink biconvex tablet coded ‘Norton 5’ on one face, ‘SERENACE’ on the other. |
Each tablet contains haloperidol 5 mg.
Excipients: Each tablet contains 120mg of lactose monohydrate.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Haloperidol |
Haloperidol is an antipsychotic belonging to the butyrophenones group. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/Aluminium blisters in packs of 30 or 100 tablets.
Not all pack sizes may be marketed.
Norton Healthcare Ltd, T/A IVAX Pharmaceuticals UK, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX, United Kingdom
PA 0282/063/006
Date of first authorisation: 17 February 1977
Date of last renewal: 17 December 2006
| Drug | Countries | |
|---|---|---|
| SERENACE | Australia, Japan, New Zealand, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
